Henry Schein (HSIC) Reports Q2 Earnings: What Key Metrics Have to Say

Henry Schein (HSIC) reported Q2 2025 results, with revenue of $3.24 billion, a 3.3% year-over-year increase that slightly beat the $3.22 billion consensus estimate. However, EPS declined to $1.10 from $1.23 year-over-year, missing the $1.18 consensus by 6.78%. While international dental revenue grew 6%, underlying metrics revealed significant year-over-year declines in key segments such as U.S. distribution (-11.4%), U.S. dental merchandise (-29.1%), and global technology (-22%), contributing to the stock's 4.7% underperformance against the S&P 500 over the last month.

Analysis

Henry Schein's (HSIC) second-quarter 2025 results reveal a challenging operational landscape despite a modest top-line beat. The company reported revenue of $3.24 billion, a 3.3% year-over-year increase that narrowly surpassed the consensus estimate by 0.6%. However, this revenue growth did not translate to profitability, as earnings per share (EPS) fell to $1.10 from $1.23 a year ago, missing Wall Street's $1.18 estimate by a significant 6.78%. A deeper examination of segment performance highlights material weakness in key areas. U.S. Distribution and Value-Added Services revenue contracted by 11.4% year-over-year, with U.S. Dental Merchandise sales declining sharply by 29.1%. Furthermore, the Global Technology segment experienced a 22% drop in sales. While the International Dental Distribution business offered a bright spot with 6% year-over-year growth, it was insufficient to offset the domestic downturn and margin erosion. This fundamental weakness is reflected in the stock's -4.7% return over the past month, a stark underperformance against the S&P 500's 1% gain.

Key Decisions for Investors

• Investors should view the slight revenue beat with caution, as the significant EPS miss and year-over-year decline underscore deteriorating profitability and margin pressure.
• Closely monitor the performance of domestic segments, as the steep 29.1% contraction in U.S. Dental Merchandise and the 11.4% fall in U.S. Distribution are primary drivers of the negative results.
• Given the stock's recent underperformance and the conflicting signals between revenue and earnings, a neutral stance may be warranted until there is clear evidence of stabilization or a turnaround in the challenged U.S. and Global Technology divisions.